Release form:
In appearance it is a round uncoated tablet with a dividing line in the middle. White tablets, 10 tablets in a blister (3 blisters) placed in a cardboard box.
Dosage form:
Oral tablets
Structure:
One tablet (weighing 992 mg ± 5.0%) contains the active ingredient: pimobendan – 10.0 mg
Excipients: citric acid, silicon dioxide, F-melt Type M, magnesium stearate.
Pharmacological properties:
ATC-vet classification code: QC01CE90 Non-glycoside cardiotonic veterinary drugs. Phosphodiesterase inhibitors.
Pimobendan is a derivative of benzeneglyoxaline-pyridazinone, non- sympathomimetic , non-glycosidic inotropic substance with potent vasodilating properties. Pimobendan has a myocardial stimulating effect by a double action: it increases the sensitivity of the cardiac myofibril to calcium and inhibits phosphodiesterase (type III). The drug also exhibits a vasodilating effect by inhibiting phosphodiesterase activity
After oral administration of the veterinary drug, the absolute bioavailability of the active ingredients is 60-63%.
Indications for use:
The tablets are used orally to treat cardiovascular disease in dogs. The indication for use is heart failure caused by dilated cardiomyotomy, insufficiency of a bicuspid or tricuspid valve, which is accompanied by characteristic symptoms: cough, shortness of breath, decreased activity or ascites
Dosage:
The dosage can range from 0.2 mg to 0.6 mg pimobendan per 1 kg of body weight per day on the recommendation of a veterinarian, as well as depending on the severity of the disease and the condition of the animal. Make sure that the dog has completely swallowed the required dose of the drug.
The daily dose is divided into two doses (see table):
Animal weight | Daily dose | Number of tablets to take (10 mg tab) | ||
---|---|---|---|---|
In the morning | In the evening | |||
5-10 kg | 2,5 mg | – | – | |
11 – 20 kg | 5 mg | – | – | |
21 – 40 kg | 10 mg | 0.5 tab. | 0.5 tab. | |
41 – 60 kg | 20 mg | 1 tab. | 1 tab. | |
more than 60 kg | 30 mg | 1.5 tab. | 1.5 tab. |
The drug can be combined with diuretics such as furosemide.
Contraindications:
Hypertrophic cardiomyopathy. Clinical conditions in which cardiac output may be increased through functional or anatomical features (eg, aortic stenosis).
Severe forms of liver failure.
Hypersensitivity of the animal to the components of the drug.
Side effect:
Rarely, there may be a mild positive chronotropic effect (heart palpitations), vomiting, transient diarrhea, anorexia, or drowsiness. However, these reactions are dose dependent and can be avoided by reducing the dose of the drug.
Use during pregnancy, lactation
Laboratory studies in rats and rabbits have not demonstrated any teratogenic, toxic effects on the fetus. However, studies have shown toxicity to pregnant females, embryotoxic effects of high doses, excretion of pimobendan in milk The
safety of the drug has not been determined for pregnant and lactating females
Use only as directed by your veterinarian and if the potential risk to the mother outweighs the risk to the fetus and puppies
Interaction with other drugs
Do not use simultaneously with calcium channel blockers (antagonists) and P-blockers!
In pharmacological studies, no interaction was observed between the cardiac glycosides UABAINA and pimobendan. The drug can be used in combination with the diuretics furosemide. Caution
Use in animals only in cases of heart failure. It is necessary to determine the exact body weight of the animal before using the drug to ensure sufficient dosage
To avoid accidental overdose, unused portions of tablets should be placed inside the blister and kept out of the reach of dogs.
Manufacturer: Cymedica sro, Czech Republic
Storage conditions:
Store in a dry, dark place and out of reach of children at a temperature not exceeding 25 ° С